Advances in natural products and antibody drugs for SLE: new therapeutic ideas

Front Pharmacol. 2023 Jul 10:14:1235440. doi: 10.3389/fphar.2023.1235440. eCollection 2023.

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune systemic disease with a wide range of clinical symptoms, complex development processes, and uncertain prognosis. The clinical treatment of SLE is mainly based on hormones and immunosuppressants. Research on novel therapy strategies for SLE has flourished in recent years, especially the emergence of new targeted drugs and natural products that can modulate related symptoms. This review discusses the current experience including B-cell targeted drugs (belimumab, tabalumab, blisibimod, atacicept, rituximab, ofatumumab, ocrelizumab, obexelimab, and epratuzumab), T-cell targeted drugs (abatacept, dapirolizumab, and inhibitor of syk and CaMKIV), cytokines targeted drugs (anifrolumab and sifalimumab), and natural products (curcumin, oleuropein, punicalagin, sulforaphane, icariin, apigenin, and resveratrol). The aim of this paper is to combine the existing in vitro and in vivo models and clinical research results to summarize the efficacy and mechanism of natural drugs and targeted drugs in SLE for the reference and consideration of researchers.

Keywords: antibody drug; immune system; natural products; systemic lupus erythematosus; treatment.

Publication types

  • Review

Grants and funding

This work is supported by the National Natural Science Foundation of China (81671600); the Natural Science Foundation of Shandong Province, China (ZR2016HM13).